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Summary
Primary hyperparathyroidism (PHPT) in multiple endocrine
neoplasia (MEN) 2A occurs in only 15-30% of patients. It is
rarely the first feature recognized in the syndrome, is general-
ly mild and is sometimes expressed only as parathyroid tu-
mors discovered during surgery for medullary thyroid carci-
noma. A predisposition to MEN 2 is caused by germline muta-
tions of the RET proto-oncogene on chromosome 10q11.2.
Genetic studies have demonstrated the association of PHPT
with a specific mutation at codon 634 (C634R). Therefore, all
codon 634 mutation carriers are at some risk for hyper-
parathyroidism and should be submitted to an early screening
of the disease. The rarity of MEN 2A-related PHPT has pre-
vented the establishment of a well-defined therapeutic strate-
gy for treating this condition, so that recommendations about
the surgical approach have been controversial. Patients with
MEN 2A should have annual screenings for hyperparathy-
roidism by serum calcium and intact parathyroid hormone lev-
el measurements. Parathyroidectomy should be considered in
all patients who have some evidence of symptomatic disease.
The objectives of parathyroid surgery are to a) obtain and
maintain normocalcemia for the longest time possible, b)
avoid iatrogenic hypoparathyroidism, and c) facilitate future
surgery for recurrent disease. Finally, most of the patients
with MEN 2A-related PHPT have mild disease and they could
be classified as asymptomatic based on the NIH consensus
conference regarding the diagnosis and management of
asymptomatic PHPT. Therefore, these patients can be fol-
lowed up safely without parathyroid surgery.
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Introduction
Primary hyperparathyroidism (PHPT) in its hereditary variants
represents only about 5% of all PHPT but it assumes several
forms, has characteristic associations, and requires special
management.
Among all syndromes of hereditary PHPT (multiple endocrine
neoplasia type 1 and type 2A, familial hypocalciuric hypercal-
cemia, neonatal severe PHPT, hyperparathyroidism-jaw tumor
syndrome, and familial isolated hyperparathyroidism) (Table I),
MEN 2A is the only one in which PHPT is not the most com-
mon endocrine feature because it occurs in approximately 19%
to 35% of affected family members (Table II) (1-3). In fact,
more frequently clinical features of the MEN 2A syndrome in-
clude medullary thyroid carcinoma (MTC) and/or C-cell hyper-
plasia in almost all affected individuals, and pheochromocy-
toma in over 50% of patients. Therefore, it has been difficult to
study the natural history of PHPT in MEN 2 because of its low
incidence and the frequent late onset of clinical manifestations
of hyperparathyroidism (4-6). Moreover, parathyroid disease is
rarely the first feature recognized in MEN 2A, is generally mild
and is sometimes expressed only as parathyroid tumors dis-
covered incidentally in MTC surgery (7). Primary hyperparathy-
roidism in MEN 2A is a disease which is different from those
observed in other hereditary neoplastic variants (i.e., MEN 1
and hyperparathyroidism-jaw tumor syndrome). In fact, the
high rate of cure achieved with well-performed parathyroid
surgery, as well as the low rate of persistence or recurrence of
the disease, demonstrate that MEN 2A-related PHPT is a
much less aggressive condition than is usually suggested (8).
Genetic aspects
RET proto-oncogene and hyperparathyroidism
Patients with primary hyperparathyroidism, either familial or
sporadic, have one or more parathyroid glands enlarged: ade-
nomas account for 80% of cases, hyperplasia for 15-20% and
carcinomas for less than 1%. In the last few years, advances
have been made in understanding the genetic event which un-
derlies parathyroid tumorigenesis. The first step along this
pathway was the demonstration of the monoclonality of these
tumors: this has been observed in carcinomas, adenomas and
even in parathyroid hyperplasia (9-11). This suggests the in-
volvement of proto-oncogenes and tumor-suppressor genes in
their pathogenesis; hence the increasing number of molecular
genetic studies on this topic (11). In this setting, a lot of interest
has been aroused by the MEN model, notably by MENIN,
which acts as a tumor suppressor gene in MEN 1 and RET,
which acts as proto-oncogene in MEN 2. Therefore, they have
been studied as possible candidates for familial and non-famil-
ial hyperparathyroidism pathogenesis. While MENIN has been
proved to be such an example, leading to the development of
both familial and sporadic parathyroid tumors (11), the role of
RET proto-oncogene is more controversial. 
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The RET gene, mapping to 10q11.2 (12), codes for a receptor
tyrosine kinase which is expressed in the developing and adult
neural ectoderm; its expression is critical for neural crest cell
growth, migration, differentiation, survival and programmed cel-
lular death (13, 14). RET sequence analysis of families with
MEN 2 has demonstrated the presence of germ-line missense
point mutations, leading to a gain of function in the tyrosine ki-
nase activity and transforming RET into a dominantly acting
oncogene (12). MEN 2 is a syndrome in which any affected tis-
sues are likely to arise from neural crest, which supports the
thesis that RET mutations may selectively provoke a neoplastic
transformation in cell types with the same embryological origin
and which expresses the proto-oncogene (15). In this regard,
doubt has been thrown upon the pathogenetic role of RET in
MEN 2 hyperparathyroidism, due to the endodermal origin of
the parathyroid (16). Furthermore, in a prospective screening
of MEN 2A patients who underwent early thyroidectomy, there
was no evidence of parathyroid disease either at the time of
surgery or after a mean follow-up of 10 years (17); thus, it has
been supposed that the elevated calcitonin levels could be re-
sponsible for parathyroid tumorigenesis. 
Now, the association of parathyroid disease with MEN 2A is re-
garded as being genetically determined. Several evidences
support this hypothesis: the parathyroid cell precursors, which
arise from the endoderm of the posterior branchial arches, ex-
press the RET proto-oncogene (13), confirming, therefore, its
tissue-specific effect; indeed, RET expression has been
demonstrated in normal parathyroid tissue, in sporadic and
MEN 2A parathyroid tumors (18), as well the MEN 2A-related
parathyroid tumors express the mutated RET gene (18); in
contrast, patients with MEN 2B, despite high levels of calci-
tonin, do not develop hyperparathyroidism. Thus, in the above
mentioned report (17), the missing evidence of hyperparathy-
roidism following early thyroidectomy is probably due to the
loss of parathyroid glands or to a likely delayed onset of dis-
ease.
Because RET is also expressed in normal tissues (i.e., C-cells,
adrenal medulla and parathyroids), it has been considered
plausible that somatic mutations in the gene might contribute to
the pathogenesis of the sporadic tumors. The transforming po-
tential of the mutant RET proto-oncogene has been demon-
strated in sporadic MTC and pheochromocytoma (19, 20); on
the contrary, somatic RET mutations have not been found in
sporadic parathyroid adenomas (18). 
RET, hyperparathyroidism and genetic testing
A germ-line RET point mutation has been described in over
92% of MEN 2 families (21, 22). Therefore, DNA testing for
RET mutations (23) has been proposed as a confirmative test
in patients with a clinical suspicion of MEN 2 syndrome and as
a predictive test in asymptomatic patients who are clinically at
risk. The high sensitivity and specificity of the molecular test
and its considerable impact in diagnosis and therapy have led
to the introduction of RET testing in routine clinical practice
(24). 
By pooling a considerable amount of MEN 2 family data, a
close relationship between genotype and phenotype has been
Table I - Hereditary disorders associated with primary hyperparathyroidism.
Hereditary disorders Inheritance Genes
Multiple endocrine neoplasia type 1 Autosomal dominant MENIN
Multiple endocrine neoplasia type 2 Autosomal dominant RET
Familial hypocalciuric hypercalcemia Autosomal dominant CaSR
Neonatal severe primary hyperparathyroidism Autosomal dominant/recessive CaSR
Hyperparathyroidism-jaw tumor syndrome Autosomal dominant PARAFIBROMIN
Familial isolated hyperparathyroidism Autosomal dominant/recessive †
† Potentially including all of the above mentioned disorders in occult forms.
Table II - Multiple endocrine neoplasia type 2 (MEN 2) syndromes.
Syndrome Clinical features Penetrance




– FMTC Medullary thyroid carcinoma 100%
– MEN 2A/FMTC with Hirschsprung disease MEN 2A or FMTC with Hirschsprung disease
– MEN 2A with cutaneous lichen amyloidosis MEN 2A with pruritic cutaneous lesions located over the upper back
Multiple endocrine neoplasia type 2B Medullary thyroid carcinoma 100%
Pheochromocytoma 150%
Marfanoid habitus >90%
Intestinal and mucosal ganglioneuromatosis >90%
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described (21, 25). MEN 2A has been associated with muta-
tions in exon 10 (codons 609, 611, 618 and 620), exon 11
(codons 634, 635, 637), exon 13 (codons 790, 791), exon 14
(V804L) and exon 15 (codon 891); mutations at codon 634 are
the most common in MEN 2A, accounting for 85% of cases
(21, 26, 27). 
Primary hyperparathyroidism occurs in about 20-30% of MEN
2A patients (28). Therefore, only some families develop the
parathyroid disease; this suggests the existence of specific
genotypes, expressing the hyperparathyroidism phenotype.
The genotype-phenotype correlation studies in MEN 2 families
show a significant association with codon 634 mutations; a re-
lationship with codons 609, 611, 618, 620, 790 and 791 has
been also described, although less frequently (21, 27, 28). 
The most common alteration at codon 634 is a TGC to CGC
(C634R) mutation, changing a cysteine to an arginine (21).
The International RET Mutation Consortium Analysis showed
a significant (P = 0.002) association between the C634R mu-
tation and the development of hyperparathyroidism. The
study pooled the data from different countries; this genotype-
phenotype correlation was statistically significant only in the
Cambridge dataset (21). If the latter is omitted from the Con-
sortium dataset, the association is no longer significant (P =
0.22) (21). In a following study of 88 MEN 2A families har-
bouring the codon 634 mutation, no significant correlation
with the familial risk of hyperparathyroidism has been found.
In the same study an age-related and a mutation-specific
penetrance of parathyroid disease has been demonstrated:
particularly, the penetrance rose after 30 years and was sig-
nificantly higher in C634R patients. It is remarkable that, de-
spite the age-specific penetrance, the risk of hyperparathy-
roidism was significant below the age of 30, affecting 44% of
patients. Thus, all codon 634 mutation carriers are at some
risk of hyperparathyroidism and should be submitted to an
early screening of the disease.
Clinical characteristics 
Because of its hereditary nature, the clinical appearance of hy-
perparathyroidism in MEN 2A is rather early in risk subjects,
around 35 years old, compared to the average 50 years old of
the sporadic form; the onset age in the MEN 1 form is around
25-30 years old.
Often, an “incidental” parathyroid tumor is detected during thy-
roid removal for MTC.
From a clinical point of view, it is characterized by mild hyper-
calcaemia, that is mainly asymptomatic: only 15-25% of the
subjects can be found with symptoms such as kidney stones
or osteoporosis (28-32). In sporadic disease, the sympto-
matic forms account for 5-10% of the cases, while in MEN 1
patients the percentage rises above 50%. In a multicentric
European retrospective study, in a sample of 67 subjects af-
fected with PHPT MEN 2A related, 84% of the cases were
found with asymptomatic hyperparathyroidism, while the re-
maining 16% were symptomatic (10 patients had kidney
stones and one patient had bone disease) (28). Serum calci-
um was slightly higher in 69% of the subjects (less than 3
mmol l-1), while in the normal range for 16% of them (28). Al-
so, both MTC and hyperparathyroidism were diagnosed at
the time of exploratory neck surgery in 75% of the sample,
while for 4% and 18% the diagnosis of PHPT was available
before or after surgery, respectively (28). Of note, patients in
whom PHPT and MTC were diagnosed synchronously often
had normal serum levels of calcium and parathyroid hormone
(PTH) and the diagnosis of PHPT was based on morphology
(enlargement of one or more glands) or histology (28). Thus,
beyond the biological behaviour of parathyroid tumors, the
earlier onset of MTC leading to an early diagnosis of PHPT
and/or a strict clinical monitoring for the development of
parathyroid disease might justify the large number of asymp-
tomatic patients.
The hypercalcaemia recurrence rate after surgery reached
12% after 8 years (4), considering that in 42% of the subjects
an adenectomy was carried out, in 31% a subtotal parathy-
roidectomy was done, and in 16% a parathyroidectomy with
auto-transplantation of one of the gland was performed. It is be
noted that the recurrence rate after subtotal parathyroidectomy
is about 50% for MEN 1, 8-12 years after surgery (33). 
The same results were obtained in two more studies from Can-
ce, O’Riordain and colleagues, where the recovery rate after
conservative surgery (removal of 1 or 2 glands in about half of
the subjects) was 100%, with a recurrence rate of 3% (30, 34).
In conclusion, the hyperparathyroidism MEN 2A related is a
clinical form less aggressive than commonly suggested, per-
haps due to a misunderstanding of its relationship with MEN1,
and does not differ from the sporadic type regarding its behav-
iour.
Management of PHPT in MEN 2A
Patients with MEN 2A should have annual screenings for hy-
perparathyroidism by serum calcium and intact PTH measure-
ments. Parathyroidectomy should be considered in all patients
with evidence of symptomatic disease. The objectives of
parathyroid surgery are to a) obtain and maintain normocal-
cemia for the longest time possible, b) avoid iatrogenic hy-
poparathyroidism and c) facilitate future surgery for recurrent
disease. Parathyroid surgery for familial PHPT continues to
evolve as a result of improved preoperative imaging and the in-
troduction of minimally invasive techniques, which includes in-
traoperative PTH assays. However, the high incidence of multi-
ple gland disease, the possible enlargement of supernumerary
glands, and a propensity for recurrent disease make MEN-re-
lated PHPT difficult to treat (7, 35, 36). 
Diagnostic modalities
The sensitivity of preoperative Tc99m-sestamibi and high-reso-
lution ultrasound for glandular disease associated with primary
hyperparathyroidism is presented in Table III. As shown, these
techniques were less reliable in detecting multiple gland hyper-
164 Clinical Cases in Mineral and Bone Metabolism 2006; 3(2): 162-166
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Table III - Sensitivity of Tc99m-sestamibi and high-resolution ultra-
sonography in primary hyperparathyroidism.
Diagnostic modalities Sensitivity (%)
Tc99m-sestamibi
– Solitary adenomas 88.44
– Multiple gland hyperplasia 44.46
– Double adenomas 29.95
– Carcinomas 33
High resolution ultrasound
– Solitary adenomas 78.55
– Multiple gland hyperplasia 34.86
– Double adenomas 16.2
– Carcinomas 100
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plasia. Among all reported cases of hyperplastic gland disease,
the sensitivity of sestamibi ranged from 0% to 100% with an
overall mean sensitivity of 44.46%. Similarly, high-resolution ul-
trasonography has an overall sensitivity of 34.86% (37).
Surgical approaches
The rarity of MEN 2A-related PHPT has prevented the estab-
lishment of a well-defined therapeutical strategy, so that rec-
ommendations about the surgical approach have been contro-
versial.
Some authors advocate total parathyroidectomy combined with
autotransplantation of parathyroid tissue, generally to the fore-
arm musculature. This approach results in about 5% of pa-
tients with permanent post-surgical hypoparathyroidism and
30% of patients with postoperative hypercalcemia. The latter
could be easily managed with removal of transplanted tissue
from the forearm with good results and little morbidity (35). 
However, others favour subtotal parathyroidectomy such as
the treatment of choice in order to decrease the risk of perma-
nent hypoparathyroidism. This technique includes biopsy or
subtotal resection of the most normal parathyroid gland fol-
lowed by removal of the three most enlarged parathyroid
glands. With this technique, persistent or recurrent hypercal-
cemia is reported in as many as 50% of patients with familial
disease; however, hypercalcemia is probably due to the failure
to remove a supernumerary gland, and not to the overgrowth
of the small hyperplastic remnant. When any technique is per-
formed, all removed parathyroid tissue must be confirmed by
frozen section and then cryopreserved for future use if the pa-
tient should develop hypoparathyroidism (31).
Recently, a more conservative approach in MEN 2A-related
PHPT has been suggested (38). This is mainly because the
disease is much less aggressive than is usually expected and
because a significant incidence (from 27% to 48%) of solitary
adenoma has been reported. In fact, hypercalcemia is fre-
quently mild and asymptomatic and the diagnosis is most often
made synchronously or after thyroidectomy for MTC. At this
time, generally, diagnosis of PHPT is based only on morpholo-
gy (enlargement of one or more glands) or on histology (hyper-
plasia or adenoma of the parathyroid). Moreover, parathyroid
disease seems to develop more rarely in patients who undergo
a total thyroidectomy for early C-cell abnormalities. Probably,
the inevitable loss of parathyroid tissue during total thyroidecto-
my decreases the incidence of parathyroid disease simply by
reducing the number of parathyroid glands at risk. All these
findings, together with the relatively low persistence or recur-
rence rate of PHPT, support the observations of less frequent
multiple gland enlargement or supernumerary gland involve-
ment. In fact, the two most important studies on patients under-
going surgical resection for MEN 2A-related PHPT demon-
strate that, independently of the resection extent, about 90% of
patients were cured. Hypercalcemia persisted in 3% and 11%
of patients, respectively. During follow-up, hypercalcemia re-
curred in 12% and 9% of patients, independently to the resec-
tion extent. Interestingly, most of the failed primary operations
and recurrences were due to insufficient exploration with an in-
ability to recognize the presence of multiglandular disease at
time of surgery (31, 36). 
The overall observations seem to support the recommenda-
tions to adopt a conservative attitude toward parathyroid
surgery, rather than a systematic total or subtotal resection.
Therefore, surgical management should focus on the preserva-
tion of parathyroid function. During the operation, all four
parathyroid glands should be identified and a careful search for
supernumerary glands should be performed. Only the macro-
scopically enlarged glands should be removed. This technique
is associated with low rate of persistent or recurrent PHPT and
it offers a better chance of avoiding postoperative hypoparathy-
roidism. It may be wise to concomitantly undertake cervical
thymectomy. If all parathyroid glands are enlarged, the least
enlarged gland or the least enlarged portion of one gland
should be preserved. Patients should have catecholamine and
metabolite measurements to rule out a diagnosis of pheochro-
mocitoma before neck exploration for parathyroidectomy. 
Surgery is the only effective long-term therapy for primary hy-
perparathyroidism. Pharmacologic therapy is necessary when
patients have a hypercalcemic crisis, but this is unusual for pa-
tients with MEN 2A. The goals of medical therapy are intra-
venous normal saline hydration (2-8 L/day) and diuresis, after
adequate intravenous hydration with furosemide. There are
several agents that are effective for transiently reducing the
serum calcium level, until a neck exploration and parathy-
roidectomy can be performed. These agents inhibit bone re-
sorption and include bisphosphonates and calcitonin.
Finally, most of the patients with MEN 2A-related PHPT have
mild disease and they could be classified as asymptomatic
based on the NIH consensus conference regarding the diagno-
sis and management of asymptomatic PHPT. Therefore, these
patients can be followed up safely without parathyroid surgery
(39).
The role of minimally invasive parathyroidectomy (MIP) in MEN
2A-related PHPT
The MIP technique has become the standard of care for spo-
radic PHPT in institutions with significant experience in this
procedure. In PHPT associated with MEN 2A, where uniglan-
dular uptake is noted on preoperative imaging, MIP may be
considered. Although it is likely that persistence and recur-
rence rates will be higher compared with the conventional cer-
vical exploration, MIP has the advantage of causing minimal
tissue trauma and thus facilitating reoperations. Moreover, MIP
may have a role in recurrent disease, when preoperative imag-
ing suggests a single focus. However, the role of intraoperative
PTH measurement to guide the resection extent is still debat-
ed, because of the significant risk of false-positive rate in pa-
tients with multiglandular disease (up to 50%). To reduce this
risk, it has been suggested that a decline in PTH serum level >
80% (not > 50%) is necessary to accept adequate excision of
parathyroid tissue (40).
Conclusion
It is difficult to study the natural history of hyperparathyroidism
in MEN 2A, because of its low incidence (5-20%) and the fre-
quent late onset of clinical features of hyperparathyroidism
compared to MEN 1.
Nonetheless, looking at the very few data available in the liter-
ature, three interesting points emerged: firstly, the examination
of pedigrees suggests that PHPT clusters in some families,
whereas other MEN 2A families might not express the trait, a
fact which suggests a sort of phenotype-genotype correlation;
secondly, PHPT in MEN 2A is mild and asymptomatic; thirdly,
there is a relatively low recurrence rate of PHPT after surgery.
These findings suggest a conservative approach in the surgical
management of MEN 2A-related PHPT.
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